Login / Signup

Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy.

Julia F SöllnerStefan BentinkChristian HesslingerThomas B LeonardMegan L NeelyNina M PatelThomas SchlangeJamie L ToddRichard ViniskoMargaret L Salisburynull null
Published in: Lung (2024)
These data suggest that the 52-gene signature can be used in patients with IPF treated with antifibrotic therapy to distinguish patients at higher risk of disease progression and mortality.
Keyphrases
  • idiopathic pulmonary fibrosis
  • cardiovascular events
  • interstitial lung disease
  • genome wide
  • copy number
  • cardiovascular disease
  • stem cells
  • rheumatoid arthritis
  • cell therapy